Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01381133 · ClinicalTrials.gov registry record · Phase 3
Adolescent Outpatient and Continuing Care Study
A Phase 3 study, sponsored by Chestnut Health Systems.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
NCT01381133: Completed Phase 3 study, sponsored by Chestnut Health Systems.
NCT01381133 is a Phase 3 study that has completed, run by Chestnut Health Systems. The registered enrollment target is 320 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01381133, a Phase 3 study, has completed, sponsored by Chestnut Health Systems.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effectiveness and cost-effectiveness of two types of outpatient treatment with and without Assertive Continuing Care (ACC) for 320 adolescents with substance use disorders. Study participants were randomly assigned to one of four conditions: (a) Chestnut's Bloomington Outpatient Treatment (CBOP) without ACC; (b) CBOP with ACC; (c) Motivational Enhancement Therapy/Cognitive Behavior Therapy-7 session model (MET/CBT7) without ACC; and (d) MET/CBT7 with ACC. Based on prior quasi and experimental studies, the investigators hypothesized that MET/CBT would be more effective and cost-effective than CBOP in terms of increasing days abstinent and decreasing substance abuse problems. Additionally, the investigators hypothesized that the groups receiving ACC would have significantly better outcomes than the groups without ACC. Lastly, the investigators hypothesized that adding ACC to MET/CBT would be the most cost-effective option in terms of days abstinent.
Interventions
- BEHAVIORAL Chestnut Bloomington Outpatient (CBOP)
- BEHAVIORAL Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)
- BEHAVIORAL Assertive Continuing Care (ACC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2002-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
What the finished NCT01381133 record still lists
NCT01381133 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 3 interventions - of which Chestnut Bloomington Outpatient (CBOP) is the first listed.
NCT01381133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01381133 about?
NCT01381133 is a clinical study titled "Adolescent Outpatient and Continuing Care Study". The purpose of this study was to evaluate the effectiveness and cost-effectiveness of two types of outpatient treatment with and without Assertive Continuing Care (ACC) for 320 adolescents with substance use disorders. Study participants were randomly assigned to one of four conditions: (a) Chestnut...
What is the current status of trial NCT01381133?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2002-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT01381133?
The interventions under investigation include: Chestnut Bloomington Outpatient (CBOP) (BEHAVIORAL), Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7) (BEHAVIORAL), Assertive Continuing Care (ACC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT01381133?
This trial is sponsored by Chestnut Health Systems, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01381133's enrollment target sits among peer trials
320 1082nd of 2000 higher than 914 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia